DSpace Repository

A noninferiority cluster-randomized controlled trial on antibiotic postprescription review and authorization by trained general pharmacists and infectious disease clinical fellows

Show simple item record

dc.contributor.author Rattanaumpawan P.
dc.contributor.author Upapan P.
dc.contributor.author Thamlikitkul V.
dc.date.accessioned 2021-04-05T03:05:31Z
dc.date.available 2021-04-05T03:05:31Z
dc.date.issued 2018
dc.identifier.issn 0899823X
dc.identifier.other 2-s2.0-85053002289
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/12747
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053002289&doi=10.1017%2fice.2018.198&partnerID=40&md5=75e55793c32aed276d014061738c46e3
dc.description.abstract Objective We compared the effectiveness of antibiotic postprescription review and authorization (PPRA) determined by infectious disease (ID) clinical fellows with that of trained general pharmacists.Methods We conducted a noninferiority cluster-randomized controlled trial in 6 general medical wards at Siriraj Hospital in Bangkok, Thailand. Three wards were randomly assigned to the intervention (ie, the pharmacist PPRA group), and another 3 wards were assigned to the control (ie, the fellow PPRA group). We enrolled all patients in the study wards who received 1 or more doses of the targeted antibiotics: piperacillin/tazobactam, imipenem/cilastatin, and meropenem. The noninferiority margin was 10% for the favorable clinical response and 1.5 defined daily doses (DDDs) for the targeted antibiotics.Results We enrolled 303 patients in the pharmacist PPRA group and 307 patients in the ID fellow PPRA group. The baseline and clinical characteristics were similar in the 2 groups. The difference in the favorable response of patients who received the targeted antibiotics (ie, the pharmacist PPRA group minus the fellow PPRA group) was 5.15% (95% confidence interval [CI], -2.69% to 12.98%); the difference in the DDD of targeted antibiotic use (ie, the pharmacist PPRA group minus the fellow PPRA group) was 0.62 (95% CI, -1.57 to 2.82). We observed no significant difference in the DDD of overall antibiotics, 28-day mortality, 28-day ID-related mortality, favorable microbiological outcome, or antibiotic-associated complications.Conclusions We confirmed the noninferiority of pharmacist PPRA in terms of favorable clinical response; however, noninferiority in targeted antibiotic consumption could not be established. Therefore, using trained general pharmacists rather than ID clinical fellows could be an alternative in a resource-limited setting. Clinical trials registration: clinicaltrials.gov identifier: NCT 01797133 © 2018 by The Society for Healthcare Epidemiology of America. All rights reserved.
dc.subject cilastatin plus imipenem
dc.subject meropenem
dc.subject piperacillin plus tazobactam
dc.subject prescription drug
dc.subject antiinfective agent
dc.subject adult
dc.subject antibiotic associated colitis
dc.subject antibiotic postprescription review and authorization
dc.subject antibiotic prophylaxis
dc.subject antibiotic therapy
dc.subject antimicrobial stewardship
dc.subject bone infection
dc.subject cardiovascular infection
dc.subject catheter infection
dc.subject central nervous system infection
dc.subject clinical outcome
dc.subject colitis
dc.subject community acquired infection
dc.subject comparative effectiveness
dc.subject controlled study
dc.subject drug cost
dc.subject drug hypersensitivity
dc.subject drug induced disease
dc.subject drug response
dc.subject drug use
dc.subject drug utilization review
dc.subject female
dc.subject gastrointestinal infection
dc.subject genital tract infection
dc.subject head and neck infection
dc.subject hospital infection
dc.subject hospital mortality
dc.subject hospital patient
dc.subject human
dc.subject infectious arthritis
dc.subject infectious disease clinical fellow
dc.subject intervention study
dc.subject length of stay
dc.subject major clinical study
dc.subject male
dc.subject medical education
dc.subject middle aged
dc.subject multicenter study
dc.subject nose infection
dc.subject pharmacist
dc.subject pharyngitis
dc.subject physician
dc.subject pneumonia
dc.subject prescription
dc.subject randomized controlled trial
dc.subject Review
dc.subject skin infection
dc.subject soft tissue infection
dc.subject surgical infection
dc.subject Thailand
dc.subject treatment response
dc.subject urinary tract infection
dc.subject aged
dc.subject communicable disease
dc.subject health care facility
dc.subject health care quality
dc.subject hospital pharmacy
dc.subject organization and management
dc.subject pharmacist
dc.subject procedures
dc.subject standards
dc.subject very elderly
dc.subject Adult
dc.subject Aged
dc.subject Aged, 80 and over
dc.subject Anti-Bacterial Agents
dc.subject Antimicrobial Stewardship
dc.subject Communicable Diseases
dc.subject Female
dc.subject Humans
dc.subject Male
dc.subject Middle Aged
dc.subject Patients' Rooms
dc.subject Pharmacists
dc.subject Pharmacy Service, Hospital
dc.subject Standard of Care
dc.subject Thailand
dc.title A noninferiority cluster-randomized controlled trial on antibiotic postprescription review and authorization by trained general pharmacists and infectious disease clinical fellows
dc.type Review
dc.rights.holder Scopus
dc.identifier.bibliograpycitation Infection Control and Hospital Epidemiology. Vol 39, No.10 (2018), p.1154-1162
dc.identifier.doi 10.1017/ice.2018.198


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics